Tempus is a technology firm founded in 2015. It primarily concentrates on personalizing cancer care by assisting doctors to collect and analyze a large quantity of clinical and molecular data. Eric lefkofsky is the CEO and the co-founder of the company. He plays a crucial role in steering the goals of Tempus to the next level. After launching Tempus O, the organization has eased the way system executes clinical data right from research databases to electronic records.
In March 2018, Tempus announced that it received additional funds amounting to $80 million from investors who have been at the top in supporting the company’s mission of battling the chronic cancer disease. Funders of Tempus included Revolution Growth, New Enterprise Association, Kinship Trust Company and the existing investors. Lefkofsky explained through the Chicago News that company would intend to use the additional funds in scaling and improving company’s projects through the analytical platform.
Tempus is at its top gear in building the most extensive database combined with molecular and clinical data that researchers and physicians can find it easy to treat cancer patients individually and efficiently. Datasets at times may be disorganized and small to deal with in oncology healthcare, hence are displayed on unstructured formats that prevent age of medical precision from being ushered in through collecting, sorting, analyzing and scaling the processed data.
Tempus has expertise workers ranging from researchers, physicians, healthcare administrators and cancer centers who are responsible for collecting, organizing and standardization of clinical data. The company applies technical operations in identifying treatment history of patients to validate the patient’s finding done by a specialized team of healthcare professionals who then uses the given data before executing in favor of patients and providers.
The Chief Executive Officer, Eric Lefkofsky showed how impossible it is for the physicians to use remote data as a way of learning from patients attended earlier. However, building essential learning system, the specialized physicians should know the exact treated patients, the kind of drugs administered, correspondences to the given medicine and the driving genomic factors of the disease helps in improving treatment outcome of cancer patients.